Azora Therapeutics Inc. (AZR)
AZR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AZR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001513525 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
No annual revenue in SEC XBRL data for this filer.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $22.0M cash; operating cash flow -$4.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 14,286,311 (2026-11-09); 23,987,587 a year earlier; 1,217,981 three years earlier. 1y figure adjusted for splits (1-for-25 overall); 3y figure adjusted for splits (1-for-25 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2026-02-06 | Source 2026-02-06 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-19 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-08-21 |
| Auditor | CBIZ CPAs P.C., Marlton, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $106K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$64.6M | -$6.6M | $22.0M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$52.0M | -$6.4M | $28.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$2.0M | -$1.6M | $4.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$2.0M | -$1.3M | $5.9M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$1.8M | -$1.8M | $4.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$2.0M | -$1.7M | $5.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$2.2M | -$1.6M | $2.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$2.1M | -$1.5M | $3.8M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3 | 2026-08-28 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-05 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-12 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-10-16 |
Source: SEC EDGAR submissions feed, 582 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.2% |
| 1 month | +24.3% |
| 3 months | -6.8% |
| Year to date | -25.6% |
| 1 year | -48.9% |
| From 52-week high | -50.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| HRTX | Heron Therapeutics Inc. | $0.2843 | -8.44% | $54.1M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier